Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 5-Year Yield-on-Cost % is 2.19 as of Aug. 07, 2026, which is 24% above its 10-year median of 1.77. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 317 Medical Devices & Instruments companies, LeMaitre Vascular ranks worse than 52.05% on this metric.
LeMaitre Vascular's yield on cost for the quarter that ended in Mar. 2026 was 2.19.
The historical rank and industry rank for LeMaitre Vascular's 5-Year Yield-on-Cost % or its related term are showing as below:
LMAT'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.06 Med: 1.77 Max: 3.23
Current: 2.19
During the past 13 years, LeMaitre Vascular's highest Yield on Cost was 3.23. The lowest was 1.06. And the median was 1.77.
LMAT's 5-Year Yield-on-Cost % is ranked worse than 52.05% of 317
companies
in the Medical Devices & Instruments industry
Industry Median: 2.43
vs LMAT: 2.19
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
LeMaitre Vascular 5-Year Yield-on-Cost % Related Terms
LMAT vs PLSE, XRAY, ATRC: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
LeMaitre Vascular (LMAT) has a 5-Year Yield-on-Cost % of 2.19 as of Aug. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on LeMaitre Vascular and its competitors. This is 24% above median its historical median of 1.77. Over the past decade, LeMaitre Vascular's 5-Year Yield-on-Cost % has ranged from 1.06 to 3.23. According to the industry distribution chart, LeMaitre Vascular ranks #165 out of 317 companies in the Medical Devices & Instruments industry, placing it in the top 52.1%.
Is LeMaitre Vascular's 5-Year Yield-on-Cost % too high?
LeMaitre Vascular's current 5-Year Yield-on-Cost % of 2.19 is 24% above median its 10-year median of 1.77. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 3.23. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.43. LeMaitre Vascular's value of 2.19 is 9.9% below this industry median. Based on the distribution chart, LeMaitre Vascular ranks #165 out of 317 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's 5-Year Yield-on-Cost % compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #165 out of 317 companies for 5-Year Yield-on-Cost %. This places LeMaitre Vascular in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.43. LeMaitre Vascular's value of 2.19 is 9.9% below this benchmark. Historically, LeMaitre Vascular's own 5-Year Yield-on-Cost % has ranged from 1.06 to 3.23 over the past decade. While the company's 10-year median is 1.77 vs. the industry median of 2.43, LeMaitre Vascular has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.43, based on 317 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current 5-Year Yield-on-Cost % of 2.19 is 9.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on LeMaitre Vascular and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current 5-Year Yield-on-Cost % is 2.19, which is 24% above median its own 10-year median of 1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.19, which is 24% above median its 10-year median of 1.77 and 9.9% below the Medical Devices & Instruments industry median of 2.43. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current 5-Year Yield-on-Cost % is 2.19 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
5-Year Yield-on-Cost %: 2.19 (24% above median its 10-year median of 1.77)
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 9.9% below the Medical Devices & Instruments median (#165 of 317)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
